List of Cell Therapies Companies in Canada - 29

Built on 30+ years of foundational expertise, Allarta’s proprietary platform is designed to overcome immune rejection, prevent cell escape and safely deliver cell and stem cell therapies. Our lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.

Biocure Technology Inc. is a biopharmaceutical company comprised of leading scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing Biosimilar technologies for cancer treatment. The CAR T-cell cancer therapy space is one of the most innovative cancer treatments currently in the market and is seeing huge global interest. Founders and management are driven by a social agenda aimed at providing a global answer to highly priced biological medicines that remain outside the reach of common people. The company has unique scientific and execution skills to address the high barriers of CAR-T cell therapy and Biosimilar technologies, therefore is well positioned to gain leadership in the rapidly growing market of CAR T-cell cancer therapy.

Our team at BriSTAR Immunotech is dedicated to the development and commercialization of innovative T cell immunotherapy products for the treatment of cancer and viral infections with urgent unmet medical needs. We leverage our proprietary STAR-T platform to engineer next-generation T cell therapies for treating hematological malignancies and solid tumors. The STAR-T platform combines the advantages of CAR-T (Chimeric Antigen Receptor T-Cell immunotherapy) and TCR-T (T Cell Receptor T-cell immunotherapy) to produce mono- or bi-specific T cell therapies. The promising antitumor actions of STAR-T cell therapies include better antigen sensitivity and stronger tumor infiltration. These properties are critical for achieving better responses in cancer patients, especially in treating solid tumors.

C3i is a one-stop shop in the development chain of cell & gene therapy. With a proven track record of 99% manufacturing success rate across over 300 clinical products, we offer in-house, turnkey services to ensure a streamlined process, eliminating the need to transfer your technology between multiple sites. With over 15 years of expertise in diverse cell manufacturing, we deliver cost-effective solutions ensuring a seamless and successful journey from process development to commercialization.

Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.

DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.

Dalhousie University is an academic institution that offers a wide range of undergraduate and graduate programs along with research opportunities.

A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen.

ExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand stem cells.

Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments.

IntelliStem, Inc. is a clinical-stage biotech that develops innovative cellular immune cancer therapy approaches. The Company has demonstrated the...

Kingston Health Sciences Centre is a healthcare provider that offers a range of medical services and healthcare solutions.

MAGIC Clinic is a healthcare clinic that provides medical services and appreciates its staff's achievements.

The McGill University Health Centre (MUHC) is a bilingual academic health network, and one of the largest and most modern in North America. We provide tertiary and quaternary care to the population of Montreal and Quebec. In other words, care that requires hospitalization, complex surgery, emergency care or specialized treatment.

McMaster University is a research university that provides post-secondary education and academic services.

Cell and gene therapy promises to one day cure any pathology; Modulari-T’s MARC Platform produces the tools to fulfill that promise.

NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases. NTx is delivering tomorrow's genetic medicines, today. For more information, please visit nanovationtx.com.

Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Our company was founded in 2016 by field-leading academics to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines. For more information, please visit www.reparerx.com. Scam Prevention Notice It has come to our attention that individuals posing as representatives of Repare Therapeutics have been engaging in fraudulent recruiting activities, offering fake job opportunities to unsuspecting candidates. These scams are designed to deceive job seekers into providing personal information or financial details under false pretenses. Please note that we will only contact you about a position that is posted on our careers page and official email communications from Repare employees will only come from a @reparerx.com email. Repare has a formal process which includes candidate application through the Repare career page (https://www.reparerx.com/careers/). If the job is not posted on the official Repare Therapeutics careers page, then it is not a legitimate position. If you have any questions or concerns regarding job opportunities at Repare Therapeutics, please don't hesitate to reach out to our HR department directly via Contact Us section (https://www.reparerx.com/contact/). Thank you for your vigilance and understanding.

RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth. RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018. RepliCel's nearest-term commercial asset is its next-generation dermal injector, RCI-02 which represents a medical device bringing unparalleled precision and consistency to dermal injections including shallow, even dispersion of dermal fillers for fine wrinkles. RCI-02 also promises to obviate the need for local anesthetic injections due to its patented skin-numbing element embedded in the device.

Sendum offers Advanced Therapy Visibility Solutions for Life Science companies. We help our customers maintain product integrity and visibility across their value chain, reducing their losses by up to 70%. Sendum’s advantage is our real-time visibility enabling a proactive response. We are the industry leader with over 60% of all active CGT clinical trials and commercially available CGT products.

Sernova (TSX: SVA) (OTCQB: SEOVF) is a clinical-stage biotechnology company that is advancing a novel cell therapy platform for the treatment of chronic diseases. Our lead program is evaluating our Cell Pouch System™ as a potential ‘functional cure’ for insulin-dependent diabetes. In addition, we have a robust pipeline that includes preclinical programs in hemophilia A and hypothyroidism.

As Canada’s engaged university, SFU works with communities, organizations and partners to create, share and embrace knowledge that improves life and generates real change.

Virogin Biotech is a biotechnology company that specializes in oncolytic virus drug development to create impactful drugs for patients with the highest medical need.